signific
recent
interest
use
convalesc
antibodi
therapi
mab
postexposur
treatment
larg
number
antibodi
ebov
focu
hand
illustr
key
point
system
perspect
antibodi
therapi
like
work
prevent
viral
entri
neutral
andor
activ
host
complement
antibodydepend
cellmedi
cytotox
adcc
function
relat
antibodi
fc
region
extent
independ
mechan
contribut
complet
clear
antibodi
cocktail
demonstr
effect
small
larg
anim
contain
least
one
mab
neutral
activ
vitro
key
compon
two
firstgener
antibodi
cocktail
name
mappbio
zmab
defyru
recent
combin
yield
zmapp
demonstr
increas
efficaci
zmapp
cocktail
three
mousederiv
mab
ebov
gp
chimer
human
igg
scaffold
cocktail
provid
compassion
use
sever
human
case
year
demonstr
revers
cours
evd
day
post
viral
challeng
zmapp
mab
alon
capabl
afford
partial
protect
guinea
pig
two
mab
neutral
activ
vitro
wherea
third
requir
complement
pathway
moreov
recent
structur
analysi
shown
none
mutat
observ
current
circul
west
africa
ebov
strain
occur
within
epitop
zmapp
nhp
convalesc
antibodi
deriv
distinct
gpvaccin
anim
provid
postexposur
protect
ebov
marv
h
postchalleng
sera
also
neutral
among
potent
neutral
antibodi
describ
date
sudvspecif
mab
murin
similar
synthet
human
mab
neutral
infect
nearli
two
log
midnanomolar
two
synthet
human
antibodi
well
provid
postexposur
protect
immunocompromis
mous
howev
protect
nhp
antibodi
therapi
yet
demonstr
sudv
postexposur
protect
nhp
filoviru
singl
mab
oppos
polyclon
igg
convalesc
antibodi
therapi
cocktail
mab
also
shown
earli
studi
indic
one
ebovspecif
mab
afford
protect
challeng
unknown
alter
increas
dose
would
made
present
two
xray
crystal
structur
complex
publish
figur
although
other
like
forthcom
singleparticl
electron
microscopi
em
reconstruct
everi
mab
three
efficaci
mab
cocktail
zmab
zmapp
recent
made
combin
data
show
human
ebovspecif
mab
murin
sudvspecif
mab
well
two
chimer
antibodi
bind
similar
locat
overal
gp
prefus
structur
name
base
chaliceandbowl
structur
avail
synthet
human
mab
competit
elisa
suggest
also
bind
sudv
gp
similar
compon
protect
cocktail
bind
within
glycan
structur
epitop
span
wherea
epitop
contain
mostli
two
structur
epitop
overlap
residu
xray
structur
combin
structur
inform
suggest
interfac
prefus
spike
particularli
suscept
thu
potenti
strategi
isol
addit
neutral
antibodi
nonantibodi
protein
therapeut
would
target
specif
region
gp
one
paradox
attribut
sudv
mab
ebov
mab
wherea
bind
low
nanomolar
dissoci
constant
leav
viru
unneutr
high
antibodi
concentr
nm
pseudotyp
authent
viral
entri
assay
contrast
much
potent
respect
gp
neutral
log
much
lower
antibodi
concentr
mab
bind
affin
micromolar
rang
much
smaller
structur
epitop
within
synthet
antibodi
panel
discov
highli
relat
term
sequenc
reason
correl
neutral
potenc
bind
howev
broader
level
appear
bind
affin
predict
neutral
potenc
neutral
predict
protect
anim
like
region
gp
contain
neutral
epitop
could
mine
extent
librari
phage
pan
mous
immun
furthermor
gp
ebov
known
undergo
subtl
conform
chang
upon
exposur
low
ph
mild
possibl
cryptic
epitop
exist
access
prefus
structur
target
use
varieti
antibodi
glycan
cap
mucinlik
domain
eg
provid
vivo
protect
usual
appear
nonneutr
vitro
possibl
due
remov
epitop
cathepsin
cleavag
late
structur
bind
data
tempt
assum
mechan
antibodi
neutral
prevent
fusionassoci
conform
chang
littl
direct
evid
initi
cell
attach
filoviru
particl
mediat
glycan
heavili
glycosyl
mucinlik
domain
far
away
site
bind
therefor
inhibit
cell
attach
like
part
addit
dia
et
al
found
block
cellular
attach
inhibit
cathepsin
l
howev
trigger
viral
membran
fusion
pathway
depend
upon
endosom
factor
catlb
low
ph
model
wherebi
neutral
antibodi
function
block
fusionassoci
conform
chang
would
necessit
complex
surviv
reason
lifetim
endosom
potenti
mechan
act
stapl
lock
two
subunit
togeth
prefus
form
structur
epitop
span
howev
mechan
would
posit
must
remain
bound
gp
throughout
matur
endosom
presum
lysosom
viral
particl
degrad
chanc
infect
similar
mechan
propos
extens
structur
epitop
contain
mostli
thu
less
clear
bind
occlud
conform
rearrang
effici
structur
mechanist
dissect
potenti
neutral
mechan
may
lend
design
new
potent
antibodi
protein
therapeut
moreov
effici
antibodymedi
protect
like
requir
mixtur
antibodi
recogn
interfac
outer
region
gp
regard
fail
provid
protect
singl
mab
nhp
might
effect
adequ
antibodi
cocktail
peptid
present
altern
antibodi
target
protein
owe
eas
synthesi
small
scale
potenti
chemic
modif
improv
featur
structur
stabil
precis
fold
peptid
util
engag
numer
energet
favor
contact
rel
larg
surfac
addit
peptid
serv
excel
tool
identifi
key
pharmacophor
act
templat
small
molecul
mimic
interact
develop
one
fdaapprov
peptid
drug
human
immunodefici
viru
type
fusion
inhibitor
fuzeon
correspond
chr
fusion
thought
fuzeon
relat
peptid
cpeptid
work
bind
nhr
segment
extendedprehairpin
intermedi
prevent
format
sixhelix
bundl
critic
membran
fusion
approach
appli
sever
class
virus
similar
concept
appli
class
ii
earli
attempt
develop
cpeptid
filovirus
yield
mix
result
one
report
show
peptid
correspond
chr
could
reduc
infect
pseudotyp
viru
albeit
high
concentr
anoth
studi
suggest
similar
peptid
littl
one
potenti
issu
develop
filoviru
cpeptid
access
put
target
transient
extend
intermedi
presum
initi
membran
fusion
event
trigger
viru
deep
within
endocyt
pathway
earli
step
requir
host
endosom
resid
protein
catlcatb
therefor
therapeut
seek
engag
mid
latestag
fusion
intermedi
extend
intermedi
would
present
endosom
compart
overcom
challeng
target
ebov
cpeptid
develop
chr
segment
local
endosom
compart
membran
conjug
cell
penetr
peptid
cpp
domain
cholesterol
one
studi
demonstr
potenc
cpeptid
inhibitor
substanti
enhanc
conjug
tat
argininerich
sequenc
refer
tatebo
antivir
activ
endosometarget
peptid
depend
tat
sequenc
nativ
ebov
chr
sequenc
mechanist
studi
suggest
peptid
act
block
membran
fusion
intermedi
although
unequivoc
demonstr
defect
evid
latestag
entri
step
howev
concentr
peptid
requir
substanti
reduct
viral
infect
like
high
cpeptid
clinic
relev
subsequ
effort
focus
gener
character
cpeptid
conjug
cholesterol
tatebo
analogu
contain
coval
side
chain
crosslink
promot
although
mechan
inhibit
appear
unspecif
peptid
also
show
activ
vesicular
stomat
viru
glycoprotein
g
cholesterolconjug
cpeptid
potent
inhibitor
ebov
glycoproteinmedi
cell
entri
interestingli
found
cholesterol
conjug
enhanc
structur
concentrationindepend
manner
result
highlight
caution
must
exercis
consid
cholesterol
conjug
cpeptid
gener
therapeut
approach
improv
antivir
activ
cpeptid
analogu
class
fusion
protein
specif
case
ebov
conjug
cholesterol
enhanc
potenc
cost
specif
moreov
side
chain
crosslink
enhanc
stabil
tatebo
variant
neutral
ph
howev
one
side
chain
crosslink
peptid
moder
higher
activ
parent
compound
tatebo
identifi
recent
mirror
imag
phage
display
strategi
util
develop
revers
chiral
peptid
dpeptid
bind
mimic
ebov
extend
although
marv
produc
ctermin
cleavag
product
sgp
secret
ebola
virusinfect
cell
fctag
version
ebov
sudv
tafv
specif
inhibit
entri
ebolavirus
marburg
viru
indic
interfer
pathway
use
filovirus
gain
entri
target
seem
like
aspect
gpmediat
viral
entri
could
target
peptid
perhap
act
start
point
develop
small
molecul
act
potenti
therapeut
candid
exampl
cyanovirin
n
cvn
small
kda
glycanbind
protein
bind
mannosecontain
oligosaccharid
thu
inhibit
viral
entri
divers
envelop
virus
possess
glycoprotein
high
densiti
oligomannos
glycosyl
site
includ
hepat
c
measl
ebov
presum
prevent
initi
viru
cvn
also
abl
delay
death
due
ebov
challeng
murin
model
although
requir
multipl
high
given
conceiv
peptid
inhibitor
prevent
attach
may
hold
promis
entri
inhibitor
would
ad
advantag
need
function
endosom
later
point
entri
pathway
might
also
suscept
inhibit
peptid
includ
interact
uniqu
advantag
small
molecul
possess
particularli
context
emerg
prophylact
postexposur
therapeut
oral
avail
would
like
requir
refriger
numer
small
molecul
therapeut
filovirus
describ
demonstr
efficaci
nonhuman
primat
compound
fall
broad
rang
mechanist
class
perhap
advanc
polymeras
inhibitor
focu
entri
inhibitor
overview
lead
compound
target
shown
tabl
roughli
speak
small
molecul
categor
follow
broadspectrum
viral
entri
inhibitor
target
host
proteas
viral
membran
ii
inhibitor
target
specif
element
filoviru
entri
gp
iii
fdaapprov
therapeut
repurpos
filovirus
mechan
action
unclear
cation
amphiphil
within
first
categori
numer
cystein
cathepsin
inhibitor
cystein
cathepsin
proteas
suscept
mechanismbas
suicid
inhibitor
epoxidecontain
diazomethanecontain
use
select
catb
inhibitor
catlcatb
inhibitor
fydmk
essenti
role
catb
accessori
role
catl
ebov
gpdepend
target
cell
entri
could
identifi
recent
effort
target
catl
includ
divers
structur
isol
librari
case
inhibit
observ
pseudotyp
viru
cellbas
entri
assay
authent
virus
case
vitro
appear
strong
absolut
depend
catb
gpmediat
entri
filovirus
ebov
tafv
bdbv
wherea
catl
less
filovirus
sudv
marv
requir
vivo
catb
catl
knockout
mice
still
suscept
ebov
infect
death
suggest
redund
proteolyt
mechan
may
moreov
ebov
readili
adapt
use
noncatb
cystein
cathepsin
least
tissu
cultur
similar
situat
may
exist
anim
thu
like
requir
filoviru
entri
inhibitor
potent
broadspectrum
inhibit
cystein
proteas
resid
endocyt
pathway
cell
target
gener
mechan
cathepsin
cleavag
may
prove
advantag
agent
could
use
endosom
virus
also
requir
proteas
sever
acut
respiratori
syndrom
coronaviru
sarscov
howev
potenti
disadvantag
may
toxic
due
loss
host
proteas
function
critic
consider
compound
may
whether
system
toxic
toler
within
requir
treatment
window
postexposur
therapi
sever
epoxidebas
cathepsin
inhibitor
welltoler
mice
upon
prolong
administr
import
factor
consider
compound
mechan
altern
target
gener
host
factor
target
viral
membran
task
accomplish
recent
aryl
methyldien
rhodanin
deriv
propos
mechan
compound
deriv
specif
intercal
membran
unlik
biogen
mammalian
cell
virion
lack
abil
repair
membran
damag
thu
capabl
bind
membran
type
inhibit
fusion
intercal
probabl
caus
defect
membran
architectur
activ
thioxo
function
lead
local
membran
damag
potent
vitro
antivir
activ
ebov
number
envelop
virus
includ
influenza
flavivirus
poxvirus
although
mice
pretreat
surviv
lethal
dose
mouseadapt
ebov
challeng
show
efficaci
postexposur
mous
model
experi
due
suboptim
pharmacokinet
profil
nonetheless
result
provid
proofofconcept
gener
membranetarget
reagent
could
serv
broadspectrum
antivir
upon
cleavag
interact
cleav
critic
trigger
membran
fusion
machineri
although
remain
determin
factor
genet
chemic
ablat
interact
shown
reduc
infect
vitro
heterozygot
mice
substanti
resist
ebov
marv
lethal
challeng
interact
challeng
class
target
antagon
small
molecul
interfaci
surfac
usual
larg
dynam
lack
deep
bind
pocket
small
molecul
could
bind
effici
occlud
nonetheless
adamantan
class
compound
eg
appear
function
prevent
gp
bind
parent
compound
identifi
small
molecul
screen
inhibit
pseudotyp
viru
infect
specif
ebov
gp
subsequ
relationship
sar
analysi
pulldown
experi
suggest
class
interact
directli
inhibit
howev
neither
direct
kd
measur
structur
evid
small
interact
report
separ
small
molecul
screen
identifi
benzodiazepin
deriv
compound
like
target
hydrophob
pocket
interfac
prefus
conform
evidenc
ablat
activ
upon
mutat
specif
gp
wherea
remain
determin
whether
compound
inhibit
interact
prevent
gpassoci
conform
chang
studi
suggest
hydrophob
pocket
serv
welldefin
small
molecul
drug
target
inhibit
ebov
infect
third
mechanist
class
includ
cation
amphiphil
isol
multipl
screen
fdaapprov
drug
exampl
select
estrogen
receptor
modul
clomiphen
use
infertil
treatment
induc
ovul
toremifien
use
breast
cancer
chemotherapeut
inhibit
ebov
infect
vitro
latestag
entri
broader
panel
cation
amphiphil
recent
shown
similar
independ
studi
identifi
use
treat
cardiac
arrhythmia
ion
channel
inhibitor
similar
properti
precis
mechan
cation
amphiphil
inhibit
viral
entri
complet
understood
appear
distinct
directli
inhibit
interact
altern
propos
mechan
includ
alloster
modul
disrupt
gener
disfunct
endolysosom
membran
interact
yetunidentifi
addit
requir
host
although
prospect
repurpos
fdaapprov
drug
use
antifiloviru
drug
appeal
standpoint
agent
alreadi
pass
safeti
studi
import
emphas
dose
like
critic
issu
compound
like
specif
treatment
window
intend
indic
use
antifiloviru
drug
may
requir
increas
amount
combat
high
viral
titer
may
go
beyond
approv
therapeut
window
nonetheless
vitro
data
compound
compel
enough
warrant
evalu
anim
addit
class
list
yermolina
et
al
report
newli
develop
antifilovir
screen
system
base
ebovgp
pseudotyp
hiv
particl
identifi
compound
select
inhibit
ebov
marv
infect
human
although
subsequ
modif
improv
antivir
activ
lead
compound
mode
entri
inhibit
remain
elucid
among
three
class
entri
inhibitor
discuss
antibodi
advanc
term
develop
although
efficaci
cocktail
zmapp
ebov
nonhuman
primat
clear
challeng
move
forward
identifi
similar
treatment
filovirus
convalesc
serum
protect
studi
marv
suggest
also
target
appropri
antibodi
therapi
furthermor
analysi
sera
nhp
treat
one
broad
vaccin
candid
mixtur
vesicular
stomat
viru
particl
contain
gp
ebov
sudv
bdbv
suggest
induct
neutral
antibodi
signific
compon
vaccineinduc
therefor
seem
like
protect
filoviru
speci
mab
cocktail
possibl
crossprotect
appropri
engin
crossneutr
cocktail
broadli
neutral
antibodi
merit
investig
addit
molecular
studi
mechan
neutral
may
yield
new
insight
develop
potent
effect
mab
futur
develop
peptid
inhibitor
viral
membran
fusion
yield
import
mechanist
insight
infect
critic
challeng
use
compound
vivo
halflif
whether
extend
intermedi
access
enough
viabl
therapeut
target
one
cpeptid
provid
clinic
util
howev
filoviru
cpeptid
ad
complic
must
deliv
endosom
suscept
cell
type
high
enough
level
induc
therapeut
effect
wherea
conjug
variou
target
agent
cpp
cholesterol
interest
straightforward
strategi
approach
may
also
divert
peptid
broad
number
cell
type
therefor
dilut
antivir
activ
furthermor
cation
peptid
gener
suffer
high
system
toxic
nonetheless
agent
could
like
serv
valuabl
research
reagent
new
peptid
could
develop
target
aspect
entri
pathway
small
molecul
entri
inhibitor
target
host
viru
may
prove
clinic
use
especi
consid
part
cocktail
compound
inhibit
viral
replic
eg
polymeras
chain
termin
critic
challeng
move
forward
identifi
compound
exhibit
therapeut
effect
anim
model
within
reason
treatment
window
evalu
compound
mous
protect
model
critic
priorit
potenti
therapeut
efficaci
antibodi
addit
mechanist
inform
specif
cation
amphiphil
benefici
basic
appli
perspect
final
one
unexplor
area
potenti
combin
antibodi
small
molecul
conjug
adc
approach
wide
popular
cancer
therapi
proofofconcept
demonstr
approach
could
leverag
specif
monoclon
antibodi
vitro
potenc
small
molecul
inhibitor
filoviru
entri
complic
process
requir
multipl
endosom
compon
inhibitor
discuss
herein
thought
function
varieti
step
includ
cell
attach
cvn
proteolyt
process
cathepsin
inhibitor
host
receptor
interact
aspect
membran
fusion
cpeptid
cation
amphiphil
antibodi
step
suscept
vivo
remain
determin
agent
target
earli
prefus
intermedi
gp
ad
advantag
requir
deliveri
endosom
function
nonetheless
strategi
seek
disrupt
specif
step
pathway
valid
vitro
vivo
therebi
pave
way
structur
chemic
approach
develop
filoviru
entri
inhibitor
